Safety and efficacy of a novel cannabinoid chemotherapeutic, KM-233, for the treatment of high-grade glioma

Christopher Duntsch, Murali Krishna Divi, Terreia Jones, Qihong Zhou, Mathangi Krishnamurthy, Peter Boehm, George Wood, Allen Sills, Bob Moore

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Objective: To test in vitro and in vivo the safety and efficacy of a novel chemotherapeutic agent, KM-233, for the treatment of glioma. Methods: In vitro cell cytotoxicity assays were used to measure and compare the cytotoxic effects of KM-233, Δ8-tetrahydrocannabinol (THC), and bis-chloroethyl- nitrosurea (BCNU) against human U87 glioma cells. An organotypic brain slice culture model was used for safety and toxicity studies. A human glioma-SCID mouse side-pocket tumor model was used to test in vivo the safety and efficacy of KM-233 with intratumoral and intra-peritoneal administration. Results: KM-233 is a classical cannabinoid with good blood brain barrier penetration that possesses a selective affinity for the CB2 receptors relative to THC. KM-233 was as efficacious in its cytotoxicity against human U87 glioma as Δ8-tetrahydrocannabinol, and superior to the commonly used anti-glioma chemotherapeutic agent, BCNU. The cytotoxic effects of KM-233 against human glioma cells in vitro occur as early as two hours after administration, and dosing of KM-233 can be cycled without compromising cytotoxic efficacy and while improving safety. Cyclical dosing of KM-233 to treat U87 glioma in a SCID mouse xenograft side pocket model was effective at reducing the tumor burden with both systemic and intratumoral administration. Conclusion: These studies provide both in vitro and in vivo evidence that KM-233 shows promising efficacy against human glioma cell lines in both in vitro and in vivo studies, minimal toxicity to healthy cultured brain tissue, and should be considered for definitive preclinical development in animal models of glioma.

Original languageEnglish (US)
Pages (from-to)143-152
Number of pages10
JournalJournal of Neuro-Oncology
Volume77
Issue number2
DOIs
StatePublished - Apr 1 2006

Fingerprint

Cannabinoids
Glioma
Safety
Dronabinol
SCID Mice
Cannabinoid Receptor CB2
KM-233
Brain
Tumor Burden
Blood-Brain Barrier
Heterografts
Animal Models
In Vitro Techniques
Cell Line

All Science Journal Classification (ASJC) codes

  • Oncology
  • Neurology
  • Clinical Neurology
  • Cancer Research

Cite this

Safety and efficacy of a novel cannabinoid chemotherapeutic, KM-233, for the treatment of high-grade glioma. / Duntsch, Christopher; Divi, Murali Krishna; Jones, Terreia; Zhou, Qihong; Krishnamurthy, Mathangi; Boehm, Peter; Wood, George; Sills, Allen; Moore, Bob.

In: Journal of Neuro-Oncology, Vol. 77, No. 2, 01.04.2006, p. 143-152.

Research output: Contribution to journalArticle

Duntsch, C, Divi, MK, Jones, T, Zhou, Q, Krishnamurthy, M, Boehm, P, Wood, G, Sills, A & Moore, B 2006, 'Safety and efficacy of a novel cannabinoid chemotherapeutic, KM-233, for the treatment of high-grade glioma', Journal of Neuro-Oncology, vol. 77, no. 2, pp. 143-152. https://doi.org/10.1007/s11060-005-9031-y
Duntsch, Christopher ; Divi, Murali Krishna ; Jones, Terreia ; Zhou, Qihong ; Krishnamurthy, Mathangi ; Boehm, Peter ; Wood, George ; Sills, Allen ; Moore, Bob. / Safety and efficacy of a novel cannabinoid chemotherapeutic, KM-233, for the treatment of high-grade glioma. In: Journal of Neuro-Oncology. 2006 ; Vol. 77, No. 2. pp. 143-152.
@article{f39a7d8fd48e493a90e1693eeac4ad05,
title = "Safety and efficacy of a novel cannabinoid chemotherapeutic, KM-233, for the treatment of high-grade glioma",
abstract = "Objective: To test in vitro and in vivo the safety and efficacy of a novel chemotherapeutic agent, KM-233, for the treatment of glioma. Methods: In vitro cell cytotoxicity assays were used to measure and compare the cytotoxic effects of KM-233, Δ8-tetrahydrocannabinol (THC), and bis-chloroethyl- nitrosurea (BCNU) against human U87 glioma cells. An organotypic brain slice culture model was used for safety and toxicity studies. A human glioma-SCID mouse side-pocket tumor model was used to test in vivo the safety and efficacy of KM-233 with intratumoral and intra-peritoneal administration. Results: KM-233 is a classical cannabinoid with good blood brain barrier penetration that possesses a selective affinity for the CB2 receptors relative to THC. KM-233 was as efficacious in its cytotoxicity against human U87 glioma as Δ8-tetrahydrocannabinol, and superior to the commonly used anti-glioma chemotherapeutic agent, BCNU. The cytotoxic effects of KM-233 against human glioma cells in vitro occur as early as two hours after administration, and dosing of KM-233 can be cycled without compromising cytotoxic efficacy and while improving safety. Cyclical dosing of KM-233 to treat U87 glioma in a SCID mouse xenograft side pocket model was effective at reducing the tumor burden with both systemic and intratumoral administration. Conclusion: These studies provide both in vitro and in vivo evidence that KM-233 shows promising efficacy against human glioma cell lines in both in vitro and in vivo studies, minimal toxicity to healthy cultured brain tissue, and should be considered for definitive preclinical development in animal models of glioma.",
author = "Christopher Duntsch and Divi, {Murali Krishna} and Terreia Jones and Qihong Zhou and Mathangi Krishnamurthy and Peter Boehm and George Wood and Allen Sills and Bob Moore",
year = "2006",
month = "4",
day = "1",
doi = "10.1007/s11060-005-9031-y",
language = "English (US)",
volume = "77",
pages = "143--152",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "2",

}

TY - JOUR

T1 - Safety and efficacy of a novel cannabinoid chemotherapeutic, KM-233, for the treatment of high-grade glioma

AU - Duntsch, Christopher

AU - Divi, Murali Krishna

AU - Jones, Terreia

AU - Zhou, Qihong

AU - Krishnamurthy, Mathangi

AU - Boehm, Peter

AU - Wood, George

AU - Sills, Allen

AU - Moore, Bob

PY - 2006/4/1

Y1 - 2006/4/1

N2 - Objective: To test in vitro and in vivo the safety and efficacy of a novel chemotherapeutic agent, KM-233, for the treatment of glioma. Methods: In vitro cell cytotoxicity assays were used to measure and compare the cytotoxic effects of KM-233, Δ8-tetrahydrocannabinol (THC), and bis-chloroethyl- nitrosurea (BCNU) against human U87 glioma cells. An organotypic brain slice culture model was used for safety and toxicity studies. A human glioma-SCID mouse side-pocket tumor model was used to test in vivo the safety and efficacy of KM-233 with intratumoral and intra-peritoneal administration. Results: KM-233 is a classical cannabinoid with good blood brain barrier penetration that possesses a selective affinity for the CB2 receptors relative to THC. KM-233 was as efficacious in its cytotoxicity against human U87 glioma as Δ8-tetrahydrocannabinol, and superior to the commonly used anti-glioma chemotherapeutic agent, BCNU. The cytotoxic effects of KM-233 against human glioma cells in vitro occur as early as two hours after administration, and dosing of KM-233 can be cycled without compromising cytotoxic efficacy and while improving safety. Cyclical dosing of KM-233 to treat U87 glioma in a SCID mouse xenograft side pocket model was effective at reducing the tumor burden with both systemic and intratumoral administration. Conclusion: These studies provide both in vitro and in vivo evidence that KM-233 shows promising efficacy against human glioma cell lines in both in vitro and in vivo studies, minimal toxicity to healthy cultured brain tissue, and should be considered for definitive preclinical development in animal models of glioma.

AB - Objective: To test in vitro and in vivo the safety and efficacy of a novel chemotherapeutic agent, KM-233, for the treatment of glioma. Methods: In vitro cell cytotoxicity assays were used to measure and compare the cytotoxic effects of KM-233, Δ8-tetrahydrocannabinol (THC), and bis-chloroethyl- nitrosurea (BCNU) against human U87 glioma cells. An organotypic brain slice culture model was used for safety and toxicity studies. A human glioma-SCID mouse side-pocket tumor model was used to test in vivo the safety and efficacy of KM-233 with intratumoral and intra-peritoneal administration. Results: KM-233 is a classical cannabinoid with good blood brain barrier penetration that possesses a selective affinity for the CB2 receptors relative to THC. KM-233 was as efficacious in its cytotoxicity against human U87 glioma as Δ8-tetrahydrocannabinol, and superior to the commonly used anti-glioma chemotherapeutic agent, BCNU. The cytotoxic effects of KM-233 against human glioma cells in vitro occur as early as two hours after administration, and dosing of KM-233 can be cycled without compromising cytotoxic efficacy and while improving safety. Cyclical dosing of KM-233 to treat U87 glioma in a SCID mouse xenograft side pocket model was effective at reducing the tumor burden with both systemic and intratumoral administration. Conclusion: These studies provide both in vitro and in vivo evidence that KM-233 shows promising efficacy against human glioma cell lines in both in vitro and in vivo studies, minimal toxicity to healthy cultured brain tissue, and should be considered for definitive preclinical development in animal models of glioma.

UR - http://www.scopus.com/inward/record.url?scp=33747835307&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747835307&partnerID=8YFLogxK

U2 - 10.1007/s11060-005-9031-y

DO - 10.1007/s11060-005-9031-y

M3 - Article

VL - 77

SP - 143

EP - 152

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 2

ER -